As GL-3 accumulates, it can cause mild to severe symptoms that may lead to serious complications, including heart attacks, strokes, and kidney failure. Fabry's disease is diagnosed more often in ...

Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.

The usual Galafold (migalastat) dosage for Fabry disease is 123 milligrams (mg) taken by mouth once every other day. It’s important to take the Galafold dosage your doctor prescribes.

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...